Scilex Holding Company, a biopharmaceutical company, focuses on developing and commercializing non-opioid management products for the treatment of acute and chronic pain. Its commercial product is ZTlido 1.8%, a prescription lidocaine topical product for the relief of neuropathic pain related with post-herpetic neuralgia, which is a form of post-shingles nerve pain. It also offers SP-102, a viscous gel formulation of corticosteroid for epidural injections that is in a Phase III clinical trial to treat lumbosacral radicular pain; SP-103, which is in Phase II clinical trail for the treatment of low back pain; and SP-104, a novel low-dose delayed-release naltrexone hydrochloride formulation that has completed Phase I clinical trial for the treatment of fibromyalgia. The company is headquartered in Palo Alto, California. Scilex Holding Company is a subsidiary of Sorrento Therapeutics, Inc.
Earnings for Scilex Holding Company (SCLX)
Earnings in 2023 (TTM): $-114,318,000
According to Scilex Holding Company's latest financial reports the company's current earnings (TTM) are $-114,318,000. The earnings displayed on this page is the company's Pretax Income.
Earnings history of Scilex Holding Company
Annual Earnings
| Year | Income Before Tax | Net Income |
|---|---|---|
| 2023 | $-114,318,000 | $-114,331,000 |
| 2022 | $-23,360,000 | $-23,364,000 |
| 2021 | $-88,419,000 | $-88,424,000 |
| 2020 | $-47,572,000 | $-47,519,000 |
| 2019 | $-178,592,000 | $-178,594,000 |